Filing Flows › bioAffinity Technologies (BIAF) › Q2 2025
bioAffinity Technologies (BIAF) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
bioAffinity Technologies (BIAF) reported revenue of $1.3M for the second quarter 2025 (Q2 2025), -47% from a year earlier and -32% from the quarter before. Operating margin was -198.2%, net loss $4.1M (319.9% of revenue).
bioAffinity Technologies, Q2 2025: revenue $1.3M (-47% year over year), operating margin -198.2%, net loss $4.1M, operating cash flow −$2.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -32% | -47% |
| Operating profit | −$2.5M | — | — |
| Net earnings | −$4.1M | — | — |
| Operating cash flow | −$2.6M | — | — |
What changed
Revenue was $1.3M in Q2 2025, down 47% year over year and down 32% from the previous quarter.
Operating costs exceeded revenue by $2.5M, an operating margin of -198.2%. Total costs fell 16% while revenue fell 47%. The quarter ended with a net loss of $4.1M, wider than the previous quarter's $2.7M loss.
Operating cash flow was −$2.6M. Non-cash charges added back $113K of depreciation and amortization and $212K of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $13K exceeded it, leaving free cash flow of −$2.7M.
Questions
What was bioAffinity Technologies' revenue in the second quarter 2025?
bioAffinity Technologies (BIAF) reported revenue of $1.3M for the second quarter 2025 (Q2 2025), -47% from a year earlier and -32% from the quarter before.
Was bioAffinity Technologies profitable in the second quarter 2025?
Operating loss was $2.5M (-198.2% of revenue) and net loss $4.1M.